Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have been given an average recommendation of “Hold” by the seven ratings firms that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $22.00.
Several equities research analysts recently issued reports on the stock. ValuEngine downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, June 10th. BMO Capital Markets raised their target price on shares of Amphastar Pharmaceuticals from $20.00 to $21.00 and gave the company a “market perform” rating in a research note on Monday, May 11th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Thursday, July 2nd. Finally, BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 7th.
In other news, EVP Yakob Liawatidewi sold 5,978 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $21.22, for a total value of $126,853.16. Following the completion of the sale, the executive vice president now directly owns 50,182 shares in the company, valued at $1,064,862.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael A. Zasloff sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $19.00, for a total transaction of $190,000.00. Following the completion of the sale, the director now owns 45,336 shares of the company’s stock, valued at $861,384. The disclosure for this sale can be found here. Insiders have sold 147,598 shares of company stock valued at $2,819,916 over the last 90 days. Company insiders own 29.80% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMPH. Aigen Investment Management LP lifted its holdings in Amphastar Pharmaceuticals by 146.6% in the first quarter. Aigen Investment Management LP now owns 3,134 shares of the company’s stock valued at $47,000 after buying an additional 1,863 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Amphastar Pharmaceuticals by 121.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,340 shares of the company’s stock valued at $120,000 after purchasing an additional 2,929 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at about $115,000. Louisiana State Employees Retirement System acquired a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $205,000. Finally, Dupont Capital Management Corp acquired a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $270,000. Institutional investors own 51.75% of the company’s stock.
Shares of NASDAQ AMPH traded down $0.33 during mid-day trading on Friday, hitting $20.02. The company had a trading volume of 283,976 shares, compared to its average volume of 231,674. The company has a market capitalization of $924.88 million, a PE ratio of 19.07 and a beta of 1.19. The firm has a 50-day simple moving average of $20.83 and a two-hundred day simple moving average of $18.28. The company has a current ratio of 2.96, a quick ratio of 1.67 and a debt-to-equity ratio of 0.12. Amphastar Pharmaceuticals has a one year low of $12.32 and a one year high of $22.85.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, May 7th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.08. Amphastar Pharmaceuticals had a net margin of 15.90% and a return on equity of 4.99%. The business had revenue of $84.69 million during the quarter, compared to the consensus estimate of $81.80 million. Sell-side analysts expect that Amphastar Pharmaceuticals will post 0.44 earnings per share for the current fiscal year.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Read More: QQQ ETF
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.